Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Depreciation & Amortization (CF): 2020-2025

Historic Depreciation & Amortization (CF) for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Sep 2025 value amounting to $6.0 million.

  • Maravai Lifesciences Holdings' Depreciation & Amortization (CF) rose 18.46% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.1 million, marking a year-over-year increase of 19.77%. This contributed to the annual value of $20.9 million for FY2024, which is 62.02% up from last year.
  • According to the latest figures from Q3 2025, Maravai Lifesciences Holdings' Depreciation & Amortization (CF) is $6.0 million, which was up 0.30% from $6.0 million recorded in Q2 2025.
  • Maravai Lifesciences Holdings' Depreciation & Amortization (CF)'s 5-year high stood at $6.0 million during Q3 2025, with a 5-year trough of $1.3 million in Q1 2021.
  • For the 3-year period, Maravai Lifesciences Holdings' Depreciation & Amortization (CF) averaged around $4.7 million, with its median value being $5.0 million (2024).
  • Per our database at Business Quant, Maravai Lifesciences Holdings' Depreciation & Amortization (CF) declined by 25.72% in 2021 and then skyrocketed by 130.10% in 2024.
  • Over the past 5 years, Maravai Lifesciences Holdings' Depreciation & Amortization (CF) (Quarterly) stood at $1.7 million in 2021, then rose by 14.38% to $2.0 million in 2022, then spiked by 97.09% to $3.9 million in 2023, then surged by 40.16% to $5.5 million in 2024, then increased by 18.46% to $6.0 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $6.0 million for Q3 2025, versus $6.0 million for Q2 2025 and $5.7 million for Q1 2025.